Blackstone Inc’s Haemonetics HAE Stock Holding History

Blackstone Inc’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$620K	Buy	8,268 +1,868	+29%	+$120K	﹤0.01%	318
2026 Q1	$361K	Buy	+6,400	New	+$417K	﹤0.01%	326

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blackstone Inc's HAE Position: Q2 2026 in Review

Blackstone Inc increased its Haemonetics (HAE) stake by 29% in Q2 2026, buying an estimated $120K and bringing the position to 8,268 shares worth $620K. The position accounts for ﹤0.01% of the portfolio, ranked #318.

Blackstone Inc first reported a position in HAE in Q1 2026 and has held it in 2 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Blackstone Inc held 8,268 shares of Haemonetics worth $620K as of Q2 2026.
Blackstone Inc bought 1,868 Haemonetics shares in Q2 2026, an estimated $120K.
Haemonetics made up ﹤0.01% of Blackstone Inc's portfolio in Q2 2026, its #318 holding.
Blackstone Inc first reported a position in Haemonetics in Q1 2026 and has held it in 2 quarters since.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.